Our finding that Elovl6 loss hampers AML propagation will facilitate the development of novel cancer treatments; ELOVL6 activity or pathways regulated by ELOVL6 are potential targets of anti-AML therapy. This evidence concerns the gene ELOVL6 and acute myeloid leukemia.